Sutro Biopharma, Inc.
STRO · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.09 | 1.00 | -13.13 | -0.50 |
| FCF Yield | -13.77% | -4.49% | -0.11% | -1.41% |
| EV / EBITDA | -7.91 | -37.48 | -39.09 | -70.62 |
| Quality | ||||
| ROIC | -91.69% | -27.77% | -36.38% | -31.77% |
| Gross Margin | 88.37% | 95.57% | 87.77% | 84.21% |
| Cash Conversion Ratio | 0.84 | 1.05 | -0.03 | 0.77 |
| Growth | ||||
| Revenue 3-Year CAGR | -2.90% | 35.44% | 16.63% | 13.13% |
| Free Cash Flow Growth | -67.89% | -2,590.44% | 95.56% | -29.46% |
| Safety | ||||
| Net Debt / EBITDA | -0.08 | 0.52 | -0.07 | -0.28 |
| Interest Coverage | -7.67 | -3.76 | -38.54 | -31.41 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -479.01 | -419.86 | -172.90 | -150.96 |